NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inivata and Collaborators Announce New D ata Demonstrating Clinical Potential of its RaDa R™ MRD Test in HR + HER2- Breast Cancer

Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced new data in support of its RaDaRTM assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The data, from the CHiRP study (Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer), has been published in the Journal of Clinical Oncology and was presented in part at the 2022 ASCO® Annual Meeting which took place 3-7 June 2022 in Chicago, IL.

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

OAKLAND, Calif.--(BUSINESS WIRE)---- $NEO #NEO--Gibbs Law Group is investigating potential legal claims on behalf of NEO investors.

Lost Money in NeoGenomics, Inc.?

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in multiple upcoming institutional investor conferences. Management will participate in investor meetings and a presentation at the William Blair 42nd Annual Growth Stock Conference in Chicago, on Wednesday, June 8, 2022.

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D FORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certification with zero deficiencies. This certification is the next step in NeoGenomics offering its global pharmaceutical partners the much-needed option to use its Suzhou laboratories for trials relating to patients in China, from early discovery translational research through clinical trial work in oncology drug development programs.

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022.

NeoGenomics Appoints Lynn Tetrault Interim CEO

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") together with collaborators will present new data on its RaDaR® assay for the detection of minimal residual disease (MRD) and recurrence at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on 3-7 June 2022. New data on the Company's InVisionFirst®-Lung liquid biopsy test will also be presented.

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting

Inivata and Collaborators to P resent New D ata F urther V alidat ing the A pplication of its RaDa R® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

Inivata and Collaborators to Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period.

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

FT MYERS, FL / ACCESSWIRE / May 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in investor meetings and a fireside chat at the BofA 2022 Healthcare Conference on Thursday, May, 12, 2022 in Las Vegas, Nevada. The fireside chat discussion is scheduled for 9:20am PT / 12:20pm ET and will be webcast live.

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Shashi Kulkarni - Chief Scientific Officer David Sholehvar - Clinical Division President Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Andrew Cooper - Raymond James Alex Nowak - Craig Hallum Capital Mark Massaro - BTIG Puneet Souda - SVB Securities Dan Brennan - Cowen Operator Good morning ladies and gentlemen. Thank you for standing by.

NeoGenomics Inc.'s (NEO) Q1 2022 Results - Earnings Call Transcript

First-Quarter 2022 Results Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services revenue increased 4% Pharma Services revenue decreased 4% to $18 million FORT MYERS, FL / ACCESSWIRE / April 27, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2022. "While our first quarter performance was disappointing and inconsistent with our company's strong track record, we are taking immediate actions to improve our operating performance and return to profitable growth.

NeoGenomics Reports Revenue of $117 Million in the First Quarter

FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost. The Lilly Lung Cancer Sponsored Testing Program will utilize the NeoTYPE® DNA and RNA Assay to provide eligible metastatic NSCLC patients with enhanced access to a targeted genomic test offering that can help physicians and patients make informed treatment decisions.

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline

NEW YORK , April 18, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - NEO

New York, New York--(Newsfile Corp. - April 16, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public.SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through...

NEO Investor Notice : ROSEN, Top Ranked Investor Counsel, Encourages NeoGenomics, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - NEO

Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has unveiled new data at the American Association for Cancer Research (AACR) Annual Meeting further demonstrating the potential of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence.

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022

Inivata and Collaborators Publish New Data on RaDaR ™ MRD Assay at AACR 2022

Inivata and Collaborators Publish New Data on RaDaR™ MRD Assay at AACR 2022

ZURICH--(BUSINESS WIRE)-- #ClinicalResearch--Biognosys' leading discovery proteomics services to add depth to NeoGenomics' multiomics solutions for biopharma clinical trials and research

Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies FORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services announced a global strategic partnership agreement with Biognosys AG, a Switzerland-based leader in next-generation proteomics solutions for drug discovery and development this week. This partnership strengthens NeoGenomics' proteomics-based product capabilities for its Pharma Services Division from early discovery translational research through clinical trial work in oncology drug development programs.

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D

FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2022, financial results on Wednesday, April 27, 2022. The Company has scheduled a webcast and conference call to discuss their first quarter 2022 results on Wednesday, April 27, 2022 at 8:30 AM EDT.

NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022

NEW YORK , April 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEO INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - NEO

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) on behalf of NeoGenomics stockholders. Our investigation concerns whether NeoGenomics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. NeoGenomics specializes in cancer genetics testing and inf

NEOGENOMICS ALERT: Bragar Eagel & Squire, P.C. is Investigating NeoGenomics, Inc. on Behalf of NeoGenomics Stockholders and Encourages Investors to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - March 31, 2022) - Holzer & Holzer, LLC is investigating whether NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) complied with federal securities laws. On March 28, 2022, the Company announced that its CEO was stepping down and further disclosed that it expects "revenue for Q1 2022 may be below the low end of its prior guidance of $118 - $120 million and EBITDA for Q1 2022 will be below the...

SHAREHOLDER ALERT: Investigation of NeoGenomics (NEO) Announced by Holzer & Holzer, LLC

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NeoGenomics, Inc. (NASDAQ: NEO) resulting from allegations that NeoGenomics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased NeoGenomics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – NEO

News for NeoGenomics Stock (NEO)